Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,629.13
(
1.89%
)
US TECH 100
23,735.20
(
1.94%
)
Dow Jones
46,562.68
(
2.16%
)
Brent Oil
96.29
(
-10.95%
)
Bitcoin
70,801.32
(
4.37%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: mcbio post# 163881

Thursday, 07/11/2013 8:22:19 PM

Thursday, July 11, 2013 8:22:19 PM

Post# of 257269
[GILD] Enrolling GT1 patients in the Sofo/Riba study is bizarre. You don't drop clean, synergistic drugs like [GS-5885] you add them. You don't seek out longer durations with less potent combinations. Why not longer durations of Sofo/5885 in GT1? Why not study GT2 patients? Couldn't longer durations in GT2 help boost SVR rates within this genotype?










Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today